PDCD1 and metastatic melanoma: Similarly, in clinical practice, though anti-CTLA-4 mAb ipilimumab has been approved as a single agent treatment for patients with metastatic melanoma, currently it is primarily being used in combination with other agents including anti-PD-1 antibodies, anti-cancer vaccines, chemotherapy and radiation6,7,42,43.